Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2022 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL

NEW HAVEN, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of...
March 29, 2022 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform

NEW HAVEN, Conn., March 29, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating a new class of transformative precision therapeutics that target and...
January 18, 2022 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program

NEW HAVEN, Conn., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a precision medicine biotechnology company, today announced the selection of its lead product candidate,...
November 18, 2021 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease

NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd....
October 19, 2021 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer

NEW HAVEN, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment...
March 01, 2021 16:00 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie...
June 10, 2019 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences Announces Corporate Progress and Financing

Finalized Series A funding, bringing total raised to date to $12MM to support proprietary platform that enables identification of disease-driving bacteria and development of therapies for inflammatory...